Side-by-side · Research reference

CartalaxvsIpamorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BPhase 1HUMAN-REVIEWED21/57 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

Ipamorelin

Selective GHRP · Ghrelin Mimetic

200–300 mcgPer doseRaun 1998

Phase 1Evidence levelRaun 1998 Sigalos 2018

~2 hrHalf-lifeRaun 1998

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Cartalax

Ipamorelin

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998 Bowers 1991

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002

Feedback intact?

—

Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

Cartalax

Ipamorelin

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Phase 1 + clinical practiceRaun 1998 Sigalos 2018

Standard dose

—

200–300 mcg per injectionRaun 1998

Anecdotal community range; clinical doses 1–3 mg IV in trials.

Frequency

—

1–3× per day

Once daily pre-sleep is most common; twice or thrice for advanced users.

Lower / starter dose

—

100 mcg per dose

Duration

—

8–12 weeks on / 4 weeks off (anecdotal)

GHS-R desensitisation reported with continuous dosing.

Reconstitution

—

Bacteriostatic water; typical 2 mL per 5 mg vial

Timing

—

Pre-sleep + fasted preferred; 30 min away from food

Half-life

—

~2 hoursRaun 1998

Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

Ipamorelin

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

Ipamorelin

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

Cortisol elevation

—

Negligible vs other GHRPsRaun 1998

Prolactin elevation

—

NegligibleRaun 1998

Hunger

—

Mild appetite increase via ghrelin-receptor crosstalk

Injection site reaction

—

Mild irritation possible

GH excess (overdose)

—

Joint pain, edema, insulin resistance

IGF-1 elevation

—

Dose-dependent; monitor with chronic high-dose use

Cancer risk

—

Theoretical via GH/IGF-1 axis; contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

Ipamorelin

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

Ipamorelin

·Untreated diabetes
·Severe insulin resistance
·Concurrent corticosteroid use (theoretical desensitisation)

05Administration Protocol

Parameter

Cartalax

Ipamorelin

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.

4. Storage

—

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Cartalax

— no documented stacks

Ipamorelin

+ Tesamorelin

Strong

View Tesamorelin →

Ipamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.

Ipamorelin: 200–300 mcg SQ · pre-sleep
Tesamorelin: 2 mg SQ · same injection · pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep depth

Raun 1998 Bowers 2002

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

CJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.

Ipamorelin: 200–300 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation matching physiological pattern

Teichman 2006 Ionescu 2006